首页|达格列净联合胰岛素泵强化治疗老年I2DM患者的临床研究

达格列净联合胰岛素泵强化治疗老年I2DM患者的临床研究

扫码查看
目的 分析达格列净联合胰岛素泵强化治疗对老年2型糖尿病(T2DM)患者的影响.方法 将老年T2DM患者按随机数字表法分为对照组和试验组.对照组给予胰岛素泵强化治疗,泵用门冬胰岛素注射液,初始剂量为0.3~0.5 U·kg-1,并根据血糖监测结果调整门冬胰岛素注射液的使用剂量,控制空腹血糖处于4.4~7.0 mmol·L-1,餐后血糖处于4.4~10.0 mmol·L-1,停用胰岛素,给予口服降糖药物.试验组在对照组治疗的基础上口服达格列净片10 mg,qd.2组患者均连续治疗12周.比较2组患者血糖波动指标[平均血糖波动幅度(MAGE)和最大血糖波动幅度(LAGE)]、外周血核因子E2相关因子2(Nrf2)、Kelch样ECH相关蛋白1(Keap1)水平、主要不良心血管事件(MACE)和药物不良反应发生情况.结果 对照组和试验组分别入组98例.治疗后,对照组和试验组的总有效率分别为83.67%(82例/98例)和92.86%(91例/98例),在统计学上差异有统计学意义(P<0.05).MAGE 分别为(3.63±0.54)和(3.38±0.49)mmol·L-1,LAGE 分别为(8.41±1.45)和(7.53±1.26)mmol·L-1,Nrf2 分别为(8.06±1.29)和(6.82±1.03)ng·mL-1,Keap1 分别为(7.22±1.07)和(6.09±0.86)ng·mL-1,在统计学上差异均有统计学意义(均P<0.05).2组MACE及药物不良反应发生率比较,在统计学上差异均无统计学意义(均P>0.05).结论 达格列净联合胰岛素泵强化治疗可有效控制老年T2DM患者血糖水平,降低血糖波动,减轻机体氧化应激反应,降低Nrf2、Keap1水平,并可能降低心血管风险.
Clinical trial of dapagliflozin combined with insulin pump intensive therapy on elderly patients with T2DM
Objective To analyze the effects of dapagliflozin combined with insulin pump intensive therapy on elderly patients with type 2 diabetes mellitus(T2DM).Methods Elderly patients with T2DM were divided into control group and treatment group according to the random number table method.The control group was given insulin pump intensive therapy(pumping insulin aspart ejection at initial dose of 0.3-0.5 U·kg-1;dose of insulin aspart was adjusted according to the blood glucose monitoring,the insulin was stopped and the oral hypoglycemic drug was given when fasting plasma glucose was controlled at 4.4-7.0 mmol·L-1 and postprandial blood glucose was 4.4-10.0 mmol·L-1),and the treatment group was treated with 10 mg of dapagliflozin tablets once a day on this basis.Both groups of patients were continuously treated for 12 weeks.Blood glucose fluctuation indicators[mean amplitude of glycemic excursions(MAGE),largest amplitude of glycemic excursions(LAGE)],peripheral blood nuclear factor erythroid 2-related factor 2(Nrf2),Kelch-like ECH associated protein 1(Keap1)and occurrence of major adverse cardiac events(MACE)and adverse drug reactions were compared between the two groups.Results Thus 98 cases were included in control group and treatment group,respectively.After treatment,the total effective rates in control group and treatment group were 83.67%(82 cases/98 cases)and 92.86%(91 cases/98 cases);MAGE values were(3.63±0.54)and(3.38±0.49)mmol·L-1;LAGE values were(8.41±1.45)and(7.53±1.26)mmol·L-1;Nrf2 levels were(8.06±1.29)and(6.82±1.03)ng·mL-1;Keap1 levels were(7.22±1.07)and(6.09±0.86)ng·mL-1(all P<0.05).There were no statistically significant differences in the incidence rates of MACE and adverse drug reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with insulin pump intensive therapy for elderly patients with T2DM can effectively control the blood glucose level,reduce the blood glucose fluctuation,relieve the body's oxidative stress response,and reduce the levels of Nrf2 and Keap1,and it may lower the cardiovascular risk.

dapagliflozin tabletinsulin pumptype 2 diabetes mellituselderlynuclear factor erythroid 2-related factor 2(Nrf2)Kelch-like ECH associated protein 1(Keap1)

李丹、金红梅、杜飞

展开 >

延边大学附属医院、延边医院内分泌科,吉林延吉 133000

达格列净片 胰岛素泵 2型糖尿病 老年 核因子E2相关因子2 Kelch样ECH相关蛋白1

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(18)
  • 5